Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
NCT00201734
Terminated
This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2016
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Tumors, Unknown Primary Tumors, Adenocarcinoma
Register for Updates
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00736619
Completed
For patients with this type of cancer, one standard treatment option is cetuximab (Erbitux®) + radiation. We wish to study the addition of albumin-bound paclitaxel (Abraxane®) to this standard regimen of cetuximab + radiation. Albumin-bound paclitaxel and cetuximab both are chemotherapy drugs which are administered by vein. Previous studies have shown that albumin-bound paclitaxel can kill head and neck cancer cells when given alone or in combination with chemotherapy. The purpose of this study... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/09/2016
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +4 locations
Conditions: HEAD & NECK Cancer
Register for Updates
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)
NCT01820312
Withdrawn
The purpose of this study is to determine if low-dose radiation therapy and the chemotherapy drug paclitaxel is effective in treating head and neck cancer that has returned after treatment with standard radiation therapy alone, but cannot be removed by surgery. The overall total dose received of both the chemotherapy and radiation therapy will be less than that typically given as standard of care; however, the Food and Drug Administration (FDA) has not evaluated the safety and effectiveness of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2016
Locations: University of Arkansas for Medical Sciences, Little Rick, Arkansas
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Metronomic Chemotherapy in Advanced Gastric Cancer
NCT02855788
Unknown
phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin, Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/02/2016
Locations: Seattle Integrative Cancer Center, Seattle, Washington +1 locations
Conditions: Metastatic Gastric Cancer, Locally Advanced Gastric Cancer
Register for Updates
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
NCT00580983
Completed
The purpose of this study is to test whether the use of advanced radiation therapy delivery techniques can spare a patient's normal tissue, including salivary glands, from radiation. This study is being done to try to reduce radiation side effects, especially mouth dryness, which happens with standard radiation methods. In order to reduce these side effects, other normal tissues may receive a different radiation dose (sometimes more) than what would have been received using standard radiation th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2016
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Head and Neck Cancer
Register for Updates
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
NCT00131963
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well doxorubicin, cyclophosphamide, and/or paclitaxel work in treating wo... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2016
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Breast Cancer
Register for Updates
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
NCT02317419
Terminated
This is a first-in-human, open-label, multi-center, Phase 1 study of RO6927005. The study will establish the safety and tolerability profile of RO6927005 and will be conducted in two parts. In Part A, the first dose escalations will be carried out using cohorts of 1 patient. Single patient cohorts will be used to investigate increasing doses until a first dose-limiting toxicity (DLT) is reached or until grade-2 related toxicity (except infusion-related reactions), whichever comes first. At leas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2016
Locations: Not set, Bethesda, Maryland +5 locations
Conditions: Cancer
Register for Updates
Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00003812
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and giving them before and with radiation therapy may be an effective treatment for limited-stage small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients who have limited-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama +47 locations
Conditions: Lung Cancer
Register for Updates
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
NCT00003387
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy before combined chemotherapy and radiation therapy is more effective than combined chemotherapy and radiation therapy alone in treating patients with non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and pacl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama +46 locations
Conditions: Lung Cancer
Register for Updates
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00003299
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin, etoposide, and paclitaxel are more effective than cisplatin and etoposide alone in treating patients with extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus etoposide with or without paclitaxel in treating patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +19 locations
Conditions: Lung Cancer
Register for Updates
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT00033553
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor to plan treatment may result in more effective radiation therapy. It is not yet known which chemotherapy and/or radiation therapy regimen is more effective in treating non-small cell lung cancer. PURPOSE: Randomized phase II trial... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2016
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +73 locations
Conditions: Lung Cancer
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00033696
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients who have limited-stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/15/2016
Locations: Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama +50 locations
Conditions: Lung Cancer
Register for Updates